NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03
Published April 24, 2024 · Recall initiated: March 27, 2024
Summary
FDA records drug Class III recall D-0441-2024, published April 24, 2024 and initiated March 27, 2024. Recalling firm: Esperion; Status: Completed; Reported quantity: 3,480 30-count bottles; Lot: Lot #, 1990305, Exp 08-31-2025. Class III means the product is not likely to cause adverse health consequences.
Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.
What to do
Voluntary: Firm initiated · Letter
Get an email if NEXLIZET has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- NEXLIZET
- Manufacturer
- Esperion
- Distributor
- Nationwide in the USA
- Lot
- Lot #, 1990305, Exp 08-31-2025
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAVancomycin Hydrochloride for Oral Solution, USP, 250 mg per 5 mL, packaged as (a) 80 mL bottle, NDCApril 24, 2024
- FDADigoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium Pharma LLC,April 24, 2024
- FDAPatient Cart, Part: 380601, a component of the da Vinci SP Surgical System, Model: SP1098April 17, 2024
- FDAEndoVive 20 Fr Safety PEG Push w/ENFit Kit (Box 2)-Indicated for enteral nutrition directly into the stomachApril 17, 2024
- FDAEndoVive 20Fr Push Standard PEG Kit (Box 2)-Indicated for enteral nutrition directly into the stomach in bothApril 17, 2024
- FDANexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: EsperionSeptember 13, 2023
Questions about this recall
Was NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03 recalled?
Yes. FDA published recall D-0441-2024 on April 24, 2024. Reported hazard: Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: NEXLIZET.